[Clinical studies with amoxicillin (Pasetocin) (author's transl)].
This paper describes briefly the results obtained with AMPC (Pasetocin) administered by oral route to 21 patients with infection of the respiratory tract. 1. There was no difference in therapeutic effect on infection of the respiratory tract between daily dosages of 1,000 mg and 750 mg (the former was orally given in 4 divided doses every 6 hours a day and the latter in 3 divided doses after meal). The response of the patients to AMPC was remarkable or satisfactory. 2. Acute aggravation symptoms associated with chronic infection of the respiratory tract showed similar improvement to single acute infection of the respiratory tract. 3. The patients presenting acute aggravation symptoms received treatment for chronic stage consisting of consecutive oral administration of AMPC (500 approximately 750 mg a day) and their prognosis was favorable. Side effects attributable to prolonged treatment were not noted. 4. The incidence of side effects can be reduced largely by rejecting form AMPC therapy the patients who are hypersensitive to drugs including penicillins.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000667:Ampicillin / Q000031:analogs & derivatives*; D002481:Cellulitis / Q000188:drug therapy; D002764:Cholecystitis / Q000188:drug therapy; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D008199:Lymphadenitis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy
D000667:Ampicillin; D000658:Amoxicillin